Endothelin-1: A mediator of pulmonary hypertension?

Pulmonary Pharmacology and Therapeutics

Volumn 11, Issue 2-3, 1998, Pages 125-132

  MacLean, M R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ATRASENTAN; BOSENTAN; CONTRACTILE PROTEIN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC OXIDE; POTASSIUM CHANNEL; SITAXSENTAN; UNCLASSIFIED DRUG;

ARTERY DILATATION; BLOOD VESSEL TONE; CONFERENCE PAPER; CYTOSKELETON; DRUG BIOAVAILABILITY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOXIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG CIRCULATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; VASOCONSTRICTION;

EID: 0032056061     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1998.0126     Document Type: Conference Paper

References (95)

1. 1. Stewart D J, Levy R D, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease. Annals Int Med 1991; 114: 464-469.
2. 2. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, Temma S, Shirakami G, Imura H, Mikawa H. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects: evidence for increased production of endothelin in pulmonary circulation. Circulation 1991; 84: 2280-2285.
3. 3. Cody R J, Haas G J, Binkley P F, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-509.
4. 4. Hemsén A. Biochemical and functional characterisation of endothelin peptides with special reference to vascular effects. Acta Physiol Scand 1991; 58: 204-213.
5. 5. Firth J D, Radcliffe P J. Organ distribution of three rat endothelin messenger RNA's and the effect of ischemia on renal gene expression. J Clin Invest 1992; 90: 1023-1031.
6. 6. Marciniak S J, Plumpton C, Barker P J, Huskison N S, Davenport A P. Localisation of immunoreactive endothelin and preendothelin in the human lung. Pulm Pharmacol 1992; 5: 175-182.
7. 7. Janakidevi K, Fisher M A, Del Vecchio P J, Tiruppathi C, Figge J, Malik A B. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol 1992; 263: C1295-C1301.
8. 8. Zamora M A, Dempsey E C, Walchak S J, Stelzner T J. BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 1993; 9: 429-433.
9. 9. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 1958; 20: 577-580.
10. 10. Voelkel N K, Weir E K. Etiologic mechanisms in primary pulmonary hypertension. In: Weir E K, Reeves J T eds. Pulmonary Vascular Physiology and Pathophysiology. New York: Marcel Dekker, 1989; 513-539.
11. 11. Singhal S, Henderson R, Horsfield K, Cumming G. Morphometry of the human pulmonary arterial tree. Circ Res 1973; 33: 190-197.
12. 12. Heath D, Edwards J E. The pathology of hypertensive pulmonary vascular disease. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958; 18: 533-547.
13. 13. Brenner O. Pathology of vessels of the pulmonary circulation. Arch Int Med 1935; 56: 211-237.
14. 14. Frid M G, Dempsey E C, Durmowicz A G, Stenmark K R. Smooth muscle cell heterogeneity in pulmonary and systemic vessels. Importance in vascular disease. Arterioscler Thromb Vasc Biol 1997; 17: 1203-1209.
15. 15. Michelakis E D, Reeve H L, Huang J M, Tolarova S, Nelson D P, Weir E K, Archer S L. Potassium channel diversity in vascular smooth muscle cells. Can J Physiol Pharmacol 1997; 75: 889-897.
16. 16. Sasaki S, Kobayashi N, Dambara T, Kira S, Sakai T. Structural organization of pulmonary arteries in the rat lung. Anat Embryol 1995; 191: 477-489.
17. 17. Horsfield K. Morphometry of the small pulmonary arteries in man. Circulation 1978; 42: 593-597.
18. 18. Haselton P C, Heath D, Brewer D B. Hypertensive pulmonary vascular disease in states of chronic hypoxia. J Pathol Bacteriol 1968; 95: 431-440.
19. 19. Heath D, Smith P, Gosney J, Mulcahy D, Fox K, Yacoub M, Harris P. The pathology of the early and late stages of primary pulmonary hypertension. Br Heart J 58: 204-213.
20. 20. Heath D. The pathology of human pulmonary hypertension. Eur Respir Rev 1993; 3: 555-558.
21. 21. Ryan U S, Glassberg M K, Nolop KB. Endothelin-1 from pulmonary artery and microvessels acts on vascular and airway smooth muscle. Cardiovasc Pharmacol 1989; 13 (Suppl 5): S57-S62.
22. 22. Maggi C A, Giuliani S, Patacchini R, Rovero P, Giachetti A, Meli A. The activity of peptides of the endothelin family in various mammalian smooth muscle preparations. Eur J Pharmacol 1989; 174: 23-31.
23. 23. Lippton H L, Hauth T A, Summer W R, Hyman A L. Endothelin produces pulmonary vasoconstriction and systemic vasodilation. J Appl Physiol 1989; 66: 1008-1012.
24. 24. Braquet P, Touvay C, Lagente V, Vilain B, Pons F, Hosford D, Chabrier P E, Mencia-Huerta J M. Effect of endothelin-1 on blood pressure and bronchopulmonary system of the guinea pig. J Cardiovasc Pharmacol 1989; 13 (Suppl 5): S143-S146.
25. 25. Fukuroda T, Kobayashi M, Ozaki S, Yano M, Miyauchi T, Onizuka M, Sugishita Y, Goto K, Nishikibe M. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol 1994; 76: 1976-1982.
26. 26. McCulloch K M, MacLean M R. Evidence for endothelin-B receptor-mediated contraction of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension in the rat. J Cardiovasc Pharmacol 1995; 26 (Suppl 3): S169-S167.
27. 27. McCulloch K M, Docherty C C, Morecroft I, MacLean M R. Endothelin-B receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol 1996; 119: 1125-1130.
28. 28. McCulloch K M, Docherty C C, MacLean M R. Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat. Br J Pharmacol 1998; 123: 1621-1630.
29. 29. Sato K, Oka M, Hasunuma K, Ohnishi M, Sato K, Kira S. Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol 1995; 269 (Part I): L668-L672.
30. 30. MacLean M R, McCulloch K M, Baird M. Endothelin ETA-and ETB-mediated vasoconstriction in rat arteries and arterioles. J Cardiovasc Pharmacol 1994; 23: 838-845.
31. 31. Hay D W P, Luttmann M A, Pulen M A, Nambi P. Functional and binding charecterization of endothelin receptors in human bronchus: evidence for a novel ETB receptor subtype. J Pharmacol Exp Ther 1998; 284: 669-677.
32. 32. LaDouceur D M, Flynn M A, Keiser S A, Reynolds E, Haleen S J K. ETA and ETB receptors coexist on rabbit pulmonary artery smooth muscle mediating contraction. Biochem Biophys Res Comm 1993; 196: 209-215.
33. 33. Fukuroda T, Ozaki S, Ihara M, Ishikawa K, Yano M, Miyauchi T, Ishikawa M, Onizuka M, Goto K, Nishikibe M. Necessity of dual blockade of ETA and ETB receptor subtypes for antagonism of endothelin-1 induced contractions of the rabbit pulmonary artery. Br J Pharmacol 1996; 117: 995-999.
34. 34. Hay D W P, Luttman M A, Beck G, Ohlstein E H. Comparison of endothelin B (ETB) receptors in rabbit isolated pulmonary artery and bronchus. Br J Pharmacol 1996; 118: 1209-1217.
35. 35. Docherty C C, MacLean M R. Endothelin-B receptors in rabbit pulmonary resistance arteries: effect of left ventricular dysfunction. J Pharmacol Exp Ther 1998; 284: 895-903.
36. 36. MacLean M R, McCulloch K M, Baird M. Effects of pulmonary hypertension on vasoconstrictor responses to endothelin-1 and sarafotoxin S6c, and on inherent tone in rat pulmonary arteries. J Cardiovasc Pharmacol 1995; 26: 882-830.
37. 37. Li H, Chen S, Chen Y, Meng Q C, Durand J, Oparil S, Elton T S. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol 1994; 77: 1451-1459.
38. 38. Li H, Elton TS, Chen F, Oparil S. Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol 1994; 266: L553-L560.
39. 39. Elton T S, Oparil S, Taylor G R, Hicks P H, Yang R, Jin H, Chen Y F. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. Am J Physiol 1992; 263: R1260-1264.
40. 40. Yorikane R, Miyauchi T, Sakai S, Sakurai T, Yamaguchi I, Sugishita Y, Goto K. Altered expression of ETB-receptor mRNA in the lung of rats with pulmonary hypertension. J Cardiovasc Physiol 1993; 22 (Suppl 8): S336-S338.
41. 41. Zamora M A, Dempsey E C, Walchak S J, Stelzner T J. BQ-123, an ETA receptor antagonist, inhibits endothelin-1 mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 1993; 9: 429-433.
42. 42. Janakidevi K, Fisher M A, Del Vecchio P J, Tiruppathi C, Figge J, Malik A B. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol 1992; 263: C1295-C1301.
43. 43. Clozel M, Breu V, Gray G A, Kalinia B, Loffler B-M, Burri K, Cassal J-M, Muller M, Neidhart W, Ramuz H. Pharmacological charecterisation of bosentan, a new orally active non-peptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228-234.
44. 44. Ohlstein E H, Nambi P, Lago A, Hay D W P, Beck G, Fong K-L, Eddy E P, Smith P, Ellens H, Elliott J D. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242. a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 1996; 276: 609-615.
45. 45. DiCarlo V S, Chen S-J, Meng Q C, Durand J, Yano M, Chen Y-F, Oparil S. ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in the rat. Am J Physiol 1995; 269: L690-L697.
46. 46. Bonvallet S T, Zamora M R, Hasunuma K, Sato K, Hanasato N, Anderson D, Sato K, Stelzner T J. BQ123, an ETA-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 1994; 266: H1327-H1331.
47. 47. Chen S-J, Chen Y-F, Opgenorth T J, Wessale J L, Meng Q C, Durand J, DiCarlo V S, Oparil S. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodelling in Sprague-Dawley rats. J Cardiovasc Pharm 1997; 29: 713-725.
48. 48. Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S. Protection from pulmonary hypertension with an orally active endothelin antagonist in hypoxic rats. Am J Physiol 1995; 268: H828-H835.
49. 49. Chen S-J, Chen Y-F, Meng Q C, Durand J, DiCarlo V S, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995; 79: 2122-2131.
50. 50. Underwood D C, Bochnowicz S, Osborn R R, Louden C S, Hart T K, Ohlstein E H, Hay DWP. Chronic hypoxia-induced cardiopulmonary changes in three rat strains: inhibition by the ET receptor antagonist, SB 217242. J Cardiovasc Pharm 1998; 31 (Suppl 1): S453-S455.
51. 51. Hasunuma K, Rodman D M, O'Brien R F, McMurtry I F. Endothelin-1 causes pulmonary vasodilatation in rats. Am J Physiol 1990; 259: H48-H54.
52. 52. Raffestin B, Adnot S, Eddahibi S, Macquin-Mavier I, Braquet P, Chabrier P E. Pulmonary vascular response to endothelin in rats. J Appl Physiol 1991; 70: 567-574.
53. 53. Eddahibi S, Raffestin B, Braquet P, Chabrier P E, Adnot S. Pulmonary vascular reactivity to endothelin-1 in normal and chronically pulmonary hypertensive rats. J Cardiovasc Pharmacol 1991; 17 (Suppl 7): S358-S361.
54. 54. Crawley D E, Lui S F, Barnes P J, Evans T W. Endothelin-3 is a potent pulmonary vasodilator in the rat. J Appl Physiol 1992; 72: 1425-1431.
55. 55. MacLean M R, Sweeney G, Baird M, McCulloch K M, Houslay M, Morecroft I. 5-hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 1996; 119: 917-930.
56. 56. MacLean M R, McCulloch K M. Influence of applied tension and nitric oxide on responses to endothelins in rat pulmonary resistance arteries: effect of chronic hypoxia. Br J Pharmacol 1998; 123: 991-999.
57. 57. Le Cras T D, Xue C, Rengasamy A, Johns RA. Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am J Physiol 1996 (Lung Cell Mol Physiol) 270: L164-L170.
58. 58. Kouyoumdjian C, Adnot S, Levame M, Eddahibi S, Bousbaa H, Raffestin B. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats. J Clin Invest 1994; 94: 578-584.
59. 59. Mathew R, Zeballos G A, Tun H, Gewitz M H. Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension. Cardiovasc Res 1995; 30: 739-746.
60. 60. Eddahibi S, Springall D, Mannan M, Carville C, Chabrier P E, Levame M, Raffestin B, Polak J, Adnot S. Dilator effect of endothelins in pulmonary circulation: changes associated with chronic hypoxia. Am J Physiol 1993; 265: L571-L580.
61. 61. Ahlborg G, Lundberg J M. Nitric Oxide-endothelin-1 interactions in humans. J Appl Physiol 1997; 1593-1600.
62. 62. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Eng J Med 1995; 333: 214-221.
63. 63. Xue C, Johns R A. Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Eng J Med 1995; 333: 1642-1644.
64. 64. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732-736.
65. 65. Sutsch G, Bertel O, Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans Cardiovasc Drugs Ther 1997; 10: 717-725.
66. 66. Sakai S, Miyauch T, Sakurai T, Yamaguchi I, Kobayashi M, Goto K, Sugishita Y. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. J Am Coll Cardiol 1996; 28: 1580-1588.
67. 67. Borgeson D D, Grantham J A, Williamson E E, Luschner A, Redfield M M, Opgenorth T J, Burnett J C. Chronic oral endothelin type A receptor antagonism in experimental heart failure. Hypertension 1998; 31: 766-770.
68. 68. Dupuis J, Stewart D J, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94: 1578-1584.
69. 69. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Amer Coll Cardiol 1994; 23: 1427-1433.
70. 70. Pacher R, Stanek B, Hulmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G. Prognostic impact of big-ET-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27: 633-641.
71. 71. Omland T, Lie R T, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-1579.
72. 72. Dupuis J, Goresky C A, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996; 81: 1510-1515.
73. 73. Kobayashi T, Miyauchi T, Sakai S, Maeda S, Yamaguchi I, Goto K, Sugishita Y. Down regulation of ET(B) receptor, but not E (A) receptor in congestive lung secondary to heart failure. Are marked increases in circulating endothelin-1 partly attributable to decreases in lung ET(B) receptor-mediated clearance of endothelin-1? Life Sci 1998; 62: 185-193.
74. 74. Okada M, Yamashita C, Okada M, Okada K. Endothelin receptor antagonists in a beagle model of pulmonary hypertension: contribution to possible therapy. J Am Coll Cardiol 1995; 25: 1213-1217.
75. 75. Ahlborg G, Ottosson-Seeberger A, Hemsen A, Lundberg J M. Central and regional hemodynamic effects during infusion of Big endothelin-1 in healthy humans. J Appl Physiol 1996; 80: 1921-1927.
76. 76. Kiely D G, Cargill R I, Struthers A D, Lipworth B J. Cardiopulmonary effects of endothelin-1 in man. Cardiovasc Res 1997; 33: 378-386.
77. 77. Cowburn P J, Cleland J G F, McArthur J D, MacLean M R, Dargie H J, McMurray J J V, Morton J J. Pulmonary and systemic responses to exogenous ET-1 in patients with left ventricular dysfunction. Cardiovasc Res (In press).
78. 78. Cowburn P J, Cleland J G F, McArthur J D, MacLean M R, Dargie H J, McMurray J J V, Morton J J. Endothelin-B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular dysfunction. J Am Coll Cardiol (In press).
79. 79. Deuchar G A, Hicks M N, Cobbe S M, Docherty C C, MacLean M R. Pulmonary responses to 5-hydroxytryptamine and endothelin-1 in a rabbit model of left ventricular dysfunction. Cardiovascular Research 1998; 38: 500-507.
80. 80. Habib F, Dutka D, Crossman D, Oakley C M, Cleland J G F. Enhanced basal nitric oxide production in heart failure. Lancet 1994; 344: 371-373.
81. 81. Cowburn P J, McArthur J D, MacLean M R, Dargie H J, McMurray J J V, Morton J J, Cleland J G F. Short-term haemodynamic effects of BQ-123, a selective endothelin-A receptor antagonist, in patients with chronic heart failure. Lancet 1998; 352: 201-202.
82. 82. Giaid A, Yanagisawa M, Langleben D, Michel R P, Levy R, Shennib H, Kimura S, Masaki T, Duguid W P, Stewart D J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
83. 83. Saleh D, Furukawa K, Tsao M S, Maghazachi A, Corrin B, Yanagisawa M, Barnes P J, Giaid A. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997; 16: 187-193.
84. 84. Cacoub P, Dorent R, Maistre G, Nataf P, Carayon A, Piette C, Godeau P, Cabrol C, Gandjbakhch I. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 1993; 71: 448-450.
85. 85. Cacoub P, Dorent R, Nataf P, Carayon A, Riquet M, Noe E, Piette J C, Godeau P, Gandjbakhch I. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 1997; 33: 196-200.
86. 86. Druml W, Steltzer H, Waldhausl W, Lenz K, Hammerle A, Vierhapper H, Gasic S, Wagner O F. Endothelin-1 in adult respiratory distress syndrome. Am Rev Respir Dis 1993; 148: 1169-1173.
87. 87. Goerre S, Wenk M, Bartsch P, Luscher T F, Niroomand F, Hohenhaus E, Oelz O, Reinhart W H. Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation 1995; 91: 359-364.
88. 88. Langleben D, DeMarchie M, Laporta D, Spanier A H, Schlesinger R D, Stewart D J. Endothelin-1 in acute lung injury and the adult respiratory distress syndrome. Am Rev Respir Dis 1993; 148 (Part I): 1646-1650.
89. 89. Yamakami T, Taguchi O, Gabazza E C, Yoshida M, Kobayashi T, Kobayashi H, Yasui H, Ibata H, Adachi Y. Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonaryhypertension during exercise. Eur Respir J 1997; 10: 2055-2060.
90. 90. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, Black C M. Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21: 1838-1844.
91. 91. Yamamoto K, Ikeda U, Mito H, Fujikawa H, Sekiguchi H, Shimada K. Endothelin production in pulmonary circulation of patients with mitral stenosis. Circ 1994; 89: 2093-2098.
92. 92. Ishikawa S, Miyauchi T, Sakai S, Ushinohama H, Sagawa K, Fusazaki N, Kado H, Sunagawa H, Honda S, Ueno H, et al. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J Thorac Cardiovasc Surg 1995; 110: 271-273.
93. 93. Chang H, Wu G J, Wang S M, Hung C R. Plasma endothelin levels and surgically correctable pulmonary hypertension. Ann Thorac Surg 1993; 55: 450-458.
94. 94. Underwood D C, Bochnowicz S, Osborn R R, Louden C S, Hart T K, Hay DWP. Chronic hypoxia-induced pulmonary hypertension in three rat strains: inhibition by the endothelin (ET) receptor antagonist SB 217242. Am J Resp Crit Care Med 1998; 157: A726.
95. 95. Rumsey W, Bertelsen D, Abbott B, DeSiato M, Stow R, Stinson-Fisher C, Murdoch W, Barthlow H, Wilson C, Bialecki R. Development and progression of pulmonary hypertension is decreased by a novel orally active endothelin-A antagonist, ZD1611. Eur Resp J 1997; 10 (Suppl 25): S433.